Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc. is a clinical-stage oncology biotechnology company dedicated to developing novel small molecule therapeutics. The company's mission is to leverage its understanding of cancer biology and medicinal chemistry to create treatments that combine both targeted and immune-mediated mechanisms to address a wide range of tumors. Headquartered in Brisbane, California, USA, Tempest Therapeutics operates within the dynamic biotechnology and pharmaceutical industries, focusing on the oncology sector. [1, 2, 4, 6, 15, 17, 20, 22, 23, 29, 31, 35]

The company's pipeline includes several clinical-stage product candidates. Key programs feature amezalpat (TPST-1120), an oral PPARα antagonist being developed for hepatocellular carcinoma (HCC), and TPST-1495, a dual antagonist of EP2 and EP4 receptors for various cancers, including familial adenomatous polyposis (FAP). Additionally, Tempest Therapeutics has expanded its portfolio to include dual-targeting CAR-T programs, such as TPST-2003, aimed at treating relapsed/refractory multiple myeloma, following an all-stock acquisition in February 2026. [2, 4, 5, 6, 17, 19, 21, 25, 27, 29, 30, 31, 33, 35]

Recent developments include the appointment of Dr. Matt Angel as President and CEO in February 2026, with Stephen Brady transitioning to Chair of the Board. [6, 8, 10, 14, 25, 26] The company has reported positive interim data for TPST-2003 in relapsed/refractory multiple myeloma and is advancing TPST-1495 into a Phase 2 study for FAP, supported by the National Cancer Institute. [6, 16, 17, 18, 25, 27] Tempest Therapeutics is actively exploring strategic alternatives to further advance its clinical programs and maximize shareholder value. [17]